In this review:
This review summarises data relevant to the use of the MF59-Adjuvanted inactivated quadrivalent influenza vaccine (Fluad®Quad) for the prevention of seasonal influenza in adults aged ≥65 years, against the background of a high burden of disease in older adults and factors that can reduce vaccine effectiveness. The effects of COVID-19 on influenza and influenza vaccination are also discussed. This review is sponsored by Seqirus (NZ) Ltd.
Please login below to download this issue (PDF)